Cosmo Bio Co

Cosmo Bio Co Receivables

The Accounts Receivable of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 3.08 B JPY. In the previous year, Accounts Receivable was 2.96 B JPY — a change of 3.95% (higher).

Receivables

3.08 BJPY

YoY

3.95%

Last updated:

Accounts Receivable of Cosmo Bio Co is 2025 3.08 B JPY. Accounts Receivable of Cosmo Bio Co was 2024 2.96 B JPY. It decreases by 3.95% higher compared to the previous year.

The Cosmo Bio Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
2.27 B JPY
Jan 1, 2019
2.44 B JPY
Jan 1, 2020
2.78 B JPY
Jan 1, 2021
2.71 B JPY
Jan 1, 2022
2.72 B JPY
Jan 1, 2023
2.80 B JPY
Jan 1, 2024
2.96 B JPY
Jan 1, 2025
3.08 B JPY
The Cosmo Bio Co Receivables history
YEARReceivablesYoY
3.08 BJPY+3.95%
2.96 BJPY+5.75%
2.80 BJPY+2.79%
2.72 BJPY+0.52%
2.71 BJPY-2.48%
2.78 BJPY+13.71%
2.44 BJPY+7.67%
2.27 BJPY+2.53%
2.21 BJPY+1.33%
2.19 BJPY-8.39%
2.39 BJPY-1.93%
2.43 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Accounts Receivable of Cosmo Bio Co is 3.08 B JPY in 2025.

Accounts Receivable of Cosmo Bio Co changed from 2.96 B JPY to 3.08 B JPY, representing a 3.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co